Mirati Therapeutics, Inc. (MRTX) News
Filter MRTX News Items
MRTX News Results
|Loading, please wait...|
MRTX News Highlights
- For MRTX, its 30 day story count is now at 7.
- Over the past 24 days, the trend for MRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about MRTX are DRUG, LUNG and TOP.
Latest MRTX News From Around the Web
Below are the latest news stories about MIRATI THERAPEUTICS INC that investors may wish to consider to help them evaluate MRTX as an investment opportunity.
Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential first-in-class oral KRASG12D selective inhibitor for clinical evaluation. KRASG12D mutations impact approximately 180,000 patients in the US and Europe, representing approximately a 2.5-fold increase in prevalence compared to KRASG12C mutations. No targeted oncology treatment options currently exist for these pat
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Biogen''s 2nd Alzheimer''s Antibody, BeiGene''s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. The iShares Biotechnology ETF (NASDAQ: IBB ), which is heavily weighted with large-cap biotech companies, has lost 13.2% compared to a steeper 27.8% pullback by the SPDR S&P Biotech (NYSE: XBI ). What Happened: This clearly suggests that the sell-off is more acute in the small-cap space. More importantly, the declines of the year came on top of sharp losses experienced by the sector in 2021. See Also: Best Biotech Socks Right Now The year was a forgettable one from the fundamental perspective too. Drug innovation dwindled, as evident from the drop in new molecular entity approvals from 50 in 2021 to 34 in 2022. The alleviation of the COVID-19 situation did not bode well for vaccine manufacturers and t...
Skillz (SKLZ) stock is worth checking on today as the company received a delisting notice from the New York Stock Exchange.
Chinese electric vehicle (EV) stocks are a chief concern among investors today as these shares see mixed trading on Thursday!
Mirati Therapeutics (MRTX) stock is rising on Thursday as investors react to a special designation from the FDA for adagrasib.
ProQR (PRQR) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (LLY).
Shares of Mirati Therapeutics Inc. undefined jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a…